| Identification | Back Directory | [Name]
[(8S)-8-(Chloromethyl)-7,8-dihydro-4-hydroxy-1-methyl-6H-thieno[3,2-e]indol-6-yl][5-[2-(1-pyrrolidinyl)ethoxy]-1H-indol-2-yl]methanone | [CAS]
1466546-45-1 | [Synonyms]
[(8S)-8-(Chloromethyl)-7,8-dihydro-4-hydroxy-1-methyl-6H-thieno[3,2-e]indol-6-yl][5-[2-(1-pyrrolidinyl)ethoxy]-1H-indol-2-yl]methanone | [Molecular Formula]
C27H28ClN3O3S | [MOL File]
1466546-45-1.mol | [Molecular Weight]
510.05 |
| Chemical Properties | Back Directory | [Boiling point ]
758.8±60.0 °C(Predicted) | [density ]
1.393±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted) | [pka]
9.39±0.40(Predicted) |
| Hazard Information | Back Directory | [Uses]
NMS-P528 is a Duocarmycin derivative that can be used as an ADC payload. NMS-P528 can be used to synthesize NMS-P945[1]. | [References]
[1] Barbara Valsasina, et al. Novel thienoduocarmycin-trastuzumab ADC demonstrates Strong Anti-tumor Efficacy with Favorable Safety Profile in Preclinical Studies. Mol Cancer Ther. 2023 Sep 19. DOI:10.1158/1535-7163.MCT-23-0315 |
|
|